GSK

British multinational pharmaceutical and biotechnology company

GSK London SE · home listing GSK NYSE ISIN GB0009252882 SEC CIK 1131399 LEI 5493000HZTVUYLO1D793
Follow GSK Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 GBP · IFRS
EPS, diluted -

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · ESEF annual reports, IFRS
Revenue and net income6 fiscal years
  • Revenue
  • Net income
£0£10B£20B£30B£40BFY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25£32.7B£5.7B
FY24£31.4B£2.6B
FY23£30.3B£4.9B
FY22£29.3B£15B
FY21£34.1B£4.4B
FY20£34.1B£5.7B
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
0%20%40%60%80%FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2572.4%24.3%17.5%
FY2471.2%12.8%8.2%
FY2371.8%22.2%16.2%
FY2267.4%21.9%51%
FY2166%18.2%12.9%
FY2065.7%22.8%16.9%
Free cash flowOperating cash flow minus capital expenditure
£0£2B£4B£6B£8BFY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25£6.4B
FY24£5.2B
FY23£5.5B
FY22£6.3B
FY21£6.8B
FY20£7.2B
Returned to shareholdersDividends paid and shares bought back
  • Dividends
  • Buybacks
£0£1B£2B£3B£4BFY20FY21FY22FY23FY24FY25
Show the numbers
YearDividendsBuybacks
FY25£2.6B£1.4B
FY24£2.4B-
FY23£2.2B-
FY22£3.5B-
FY21£4B-
FY20£4B-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • GSK
  • Healthcare median
−100%−50%0%50%100%FY20FY21FY22FY23FY24FY25
Show the numbers
YearGSKHealthcare median
FY2517.5%−30.8%
FY248.2%−47%
FY2316.2%−58%
FY2251%−80.4%
FY2112.9%−71.9%
FY2016.9%−62.2%